Friday, 20 November 2026Read the signal. Shape what comes next.
Higher Ed Signal
Get the Signal Brief
Exterior of the Center for iPS Cell Research and Application at Kyoto University, with a sign showing the CiRA logo and bilingual name in English and Japanese, beside a building facade and leafless young trees.

Institutional development · Research, innovation and assessment · Japan

RIKEN and Kyoto University team curbs epilepsy-linked neural overactivity in brain organoids

A joint group from RIKEN, Kyoto University and Tohoku Institute of Technology designed antisense oligonucleotides that reduced excess neural activity in brain organoids grown from epilepsy patients' iPS cells.

Photo: Jun Seita / Wikimedia Commons, CC BY 2.0

Why it matters: The group said the result could help develop treatments for hereditary epilepsy that act on the disease's cause, alongside existing seizure-suppressing drugs.

According to Kyoto University, a joint group including researchers at RIKEN's BioResource Research Center, Kyoto University and Tohoku Institute of Technology designed antisense oligonucleotides (ASOs), a nucleic-acid drug candidate, targeting RNA involved in causing a hereditary epilepsy.

The team grew three-dimensional, cerebral-cortex-like brain organoids from induced pluripotent stem (iPS) cells of patients with benign adult familial myoclonic epilepsy (BAFME), reproduced the condition's neuronal hyperexcitability and studied the molecular mechanisms behind it.

The university said adding ASOs that bind the disease-related RNA reduced the abnormal neural activity in the organoids.

The work appeared online in Cell Reports Medicine on 13 November (14 November Japan time), and the group expects it to support therapies acting on the disease's cause alongside existing seizure-suppressing drugs.

Editor’s view

Scott James, Research and Innovation Editor

The researchers reported the effect in brain organoids derived from BAFME patients' cells, and the group expects the finding to support development of treatments aimed at the disease's cause, in addition to existing drugs that suppress seizures.

Keep reading

See all